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INTRODUCTION AND LITERATURE REVIEW 
 Cancer is a disease encountered universally. In 2016 it was ranked as the second leading 
cause of death in the United States (19). One negative side effect of cancer that dramatically affects 
cancer prognosis and progression is the development of cancer cachexia. Cancer cachexia is 
defined as cancer associated loss of body weight, predominantly muscle loss (9). It is estimated 
that cancer cachexia is responsible for the death of 20-40% of all cancer patients depending on the 
type of cancer (9,10). Current treatments for cancer cachexia thus far have proven ineffective and 
there is increasing evidence that cancer cachexia, once developed, is largely irreversible (9,10). 
Therefore, efforts to understand the causes of cancer cachexia progression are critical. 
 A primary factor in the development of cachexia is increased resting energy expenditure 
and decreased energy intake (17). During cancer progression, tumors rely primarily on glycolytic 
metabolism, known as the Warburg effect (11). The resulting tumor growth is explained by a 
process called the Cori cycle, in which glucose production is increased due to glucose recycling, 
predominantly occurring in the liver. The liver is necessary in energy regulation and utilization 
due to the process of gluconeogenesis, possibly another reason for cachexia to advance further (3, 
17).  This highly inefficient system is at least partially responsible for increased energy demands 
of the tumor-bearing state, thus tissues responsible for energy utilization may hold key information 
in the initial stages of cachexia development. The liver is known to be a predominant regulator of 
whole body metabolism, mediating the storage and breakdown of glycogen and fatty acids for 
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Carbohydrate Metabolism and the Liver 
 Currently, little is known about liver metabolism in the development of cancer cachexia. 
Though there is not a lot of research in functions of the liver as it relates to cancer cachexia, Narsale 
et. al. (14) found that cancer cachexia resulted in hepatic hypertrophy, decreased liver glycogen 
content and inflammation (14).  This revealed that cancer has a significant impact on the liver, 
specifically liver metabolism, and may in turn play an important role in the development of the 
cachectic phenotype (14). However, this study only examined liver metabolism after the 
development of cachexia. Although there is some research revealing alterations in glycogen 
content of the liver as a result of cancer cachexia, it is still not completely known how cancer also 
affects lipid and oxidative metabolism during early, pre-cachectic phases and throughout cancer 
progression.  
Lipid Metabolism and the Liver 
 Though there is still more research needed to fully understand the role of lipids and the 
liver during progression of cancer cachexia, Petruzzelli & Wagner (17) did find that lipid and 
oxidative metabolism were severely affected, with specifically an observed increase in lipid 
breakdown. Fatty acids in the liver are important in storing and circulating forms of energy via 
lipolysis (15). Das et. al (7) found that lipolysis was increased in cancer patients as assessed by 
increased adipose triglyceride lipase activity, but however the relationship between cachexia 








Oxidative Metabolism and the Liver 
 The main organelles of oxidative metabolism are the mitochondria. Previous research has 
found damage to liver mitochondria to precede impaired whole body metabolism (18). One study 
found that the liver of cachectic rats revealed a decrease in mitochondrial enzyme activities and 
ATP concentration (8). Therefore, mitochondrial dysfunction during the advancement of cancer 
could dramatically affect energy homeostasis for the entire body (8). Some research has shown 
that hepatic oxidative phosphorylation is decreased in a cancerous rat model and is associated with 
increased energy demand (17). Therefore, disrupted oxidative capacity and metabolism in the liver 
could possibly contribute to development of cancer cachexia. 
Purpose/Hypothesis 
 While previous research on cancer cachexia has mainly focused on muscle physiology, 
more research in other metabolic tissues is necessary to understand the whole body pathology of 
cancer. Due to the fact that 30-80% of cancer patients experience severe weight loss, there remains 
a need for research on cancer cachexia because of its impact on survival and quality of life in 
cancer patients (21). However, the effect of cancer on liver metabolism and subsequent muscle 
wasting during cachexia remains elusive. Therefore, the purpose of this study was to identify 
alterations in liver metabolism of tumor-bearing mice by analyzing stained liver sections 
throughout the progression of Lewis Lung Carcinoma (LLC) induced cancer cachexia. We 
examined glycogen and lipid content, as well as markers of oxidative quality by performing 
histological staining techniques in the livers of mice during the progression of cancer cachexia. 
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We hypothesized that markers of mitochondrial oxidation, glycogen content and lipid metabolism 
would decline in the liver as cancer cachexia progresses.  
Proposed Methods 
Animals and Interventions 
 All animal experiments were performed at the University of Arkansas and were approved 
by the Institutional Animal Care and Use Committees of the University of Arkansas, Fayetteville.  
LLC Tumor Implantation and Tissue Collection 
 C57BL/6J mice, which are a commonly used mouse for this type of research, were used in 
this experiment and purchased from Jackson Laboratories (13). The mice were kept on a 12 hours 
light, 12 hours dark cycle with full access to food and water throughout the course of the study. At 
8 weeks of age the mice were sedated with isoflurane and were injected with 1X106 Lewis Lung 
Carcinoma Cells in the left posterior leg, which is a commonly accepted method for inducing 
cancer cachexia in mice (6). For the control group, the mice were injected with 100 μL sterile 
phosphate buffered saline (PBS) which is a frequently used and accepted type of injection for 
control groups. Cancer was allowed to progress for 1, 2, 3 or 4 weeks. The experimental groups 
included the PBS, 1wk, 2wk, 3wk, and 4wk of cancer progression, with 12-16 mice in each group. 
The PBS control group was matched by age to the most cachectic group, in which it was 4 weeks 
post-implantation, but the animals were 12 weeks of age at the time of tissue collection. The tissues 
were collected directly after the animals were sedated with isoflurane before euthanasia. Sections 
of liver were then be cut at 10-12 μm using a Leica CM1950 clinical cryostat. 
 
 
Histological Staining  
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 A subset of ~8 mice/group were used for staining. After mice were euthanized under 
anesthesia and the liver sample is cut, the tissue was frozen in a position that the tissue fibers were 
perpendicular to the bottom of the mold in an OCT (optimal cutting temperature) media-freezing 
compound chilled previously in liquid nitrogen. We then wrapped the tissue block in aluminum 
foil and stored in -80°C. Next, we cut the liver tissue cross-sections (10-12 μm) using a Leica 
CM1859 clinical cryostat and mounted the sections on a positive charged glass slide. These were 
stored at -80°C until the stain was performed. 
 SDH Stain and Analysis 
 The protocol for the SDH stain we used is based on our laboratory protocol for staining 
liver tissue to determine if there is a change in mitochondrial SDH activity as an indicator of 
oxidative capacity. When we were ready to perform the SDH stain, we placed the slide with the 
liver section in a chamber and incubated it in a prewarmed Incubation Solution (50 mM Soduim 
succinate, 50 mM Phosphate buffer, 0.12M KH2PO4 & 0.88M Na2HPO4, 0.5 mg/ml Nitroblue 
tetrazoliumand) for 40 min in a 37°C water bath. We washed the samples in distilled water for 3 
minutes, and let water dry from slide glass. We used Glycerol-based mounting medium (0.12 M 
KH2PO4 and 0.88 M Na2HPO4) to mount the slide, and then finally sealed the slide with clear 
nail polish.   
Oil Red O Stain and Analysis 
 When we are ready to stain, we let slides dry at room temperature for 10-15 minutes. We 
fixed slides in 3.7% formaldehyde for 10 minutes and then quickly rinse in distilled water. We 
then placed the slides in 60% isopropyl alcohol (60 ml isopropyl alcohol, volume up to 100 ml 
with distilled water) in distilled water on a gentle shaker, and after, placed the slides in Oil Red O 
working solution (4:6 ratio of distilled water to stock Oil Red O) for 30 minutes also on a gentle 
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shaker. Next, rinsed the slides for 3 minutes in tap water and then placed slides in hematoxylin 
(heat and filtered before use) for 1 minute. We rinsed the slides in tap water for 3 minutes and then 
rinsed for 3 more minutes in distilled water. Finally, dried the slides, mounted with a small drop 
of glycerol and sealed with clear nail polish. In order to remove stain from slides, cleaned with 
100% xylenes. 
Periodic acid–Schiff (PAS) Stain 
 The PAS protocol is used to stain for glycogen in the tissue (20). First, we placed the 
coverslips with the sections of liver tissue in a columbia staining dish (Thomas Scientific #8542- 
E40). We then added Carnoy’s fixative (prepared in fume hood with 60 ml 100% alcohol, 30 ml 
Chloroform, 10 ml Glacial acetic acid) to the dish and let sit for 10 minutes. Next, rinsed the slides 
carefully with deionized water before adding the Periodic acid solution (prepared fresh for each 
stain, Periodic acid 50 mg dissolved in 10 ml deionized water) to the staining dish for 10 minutes. 
Once again, we rinsed the slides carefully with deionized water. We then added the Schiff Reagent 
(Harleco 6073/71) and let sit for 5 minutes before washing with tap water. Then, we dehydrated 
in ascending alcohol solutions (50%, 70%, 80%, 95% x 2, 100% x 2) in the columbia staining dish 
(Thomas scientific #8542-E30). We then cleared the slides with xylene (3-4x) also in the columbia 
staining dish. Lastly, we mounted the coverslips onto a labeled glass slide with glycerol mounting 
medium and secured with clear nail polish. 
Image Analysis 
 We accumulated images with the Nikon Sight DS-Vi1 camera mounted on an Olympus 
CKX41 inverted microscope. Once the images were collected, we analyzed the images with Nikon 
Basic Research Imaging Software. For each of the stains, image analysis was performed by taking 
images of the slides using 20X on the Olympus microscope, with exposure time being the same 
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for all images (1-2ms). In order to highlight the darker portions of the image (SDH, lipids and 
glycogen), we went to “Binary” in the top tool bar of the software and define the threshold, which 
allowed us to analyze the area and intensity of stain of the images. 
Statistical Analysis 
 The time groups (PBS v. 1wk v. 2wk v. 3wk v. 4wk) were the independent variables. With 
alpha (α) set at 0.05, the results were analyzed by one-way analysis of variance (ANOVA). When 
the F test was significant we used a Tukey post-hoc to determine differences between means.  
Results 
Hepatic hypertrophy in the development of cancer-cachexia 
 When compared to PBS control, 4 wk animals had 30% larger livers in 4 wk animals 
compared to all other groups (~1000mg compared to ~1300 mg) at the end of cancer progression 
(p<0.0001). Development of cachexia was evident as there were differences in muscle mass 
between 1 and 4 wk animals, as shown by Brown et al (5). 
Hepatic oxidative phenotype in progression of cancer-cachexia 
Using the SDH stain, we found there no statistical differences in the percent area stained, 
p= 0.1884) or sum intensity of stain (p= 0.1387) over time of cancer progression (Fig. B and C). 
Hepatic lipid content 
Using the Oil Red O stain, there were also no statistical differences found in percent area 




Hepatic glycogen content 
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The effect size revealed that there were some differences between 3 wk animals and 1 and 
2 wk animals for percent area stained (p= 0.0094), but no differences detected between 4 wk 
animals. There were no statistical differences found in mean intensity (p= 0.4632) or sum intensity 
of stain (p= 0.1758). 








                     Figure B                                                                                    Figure C 
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                           Figure E                                                                            Figure F 
 
Figure A: Liver Mass from current study. Figure B: SDH % Area. Figure C: SDH Intensity of 
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Discussion 
 In summary, our results suggest that liver hypertrophy occurs over progression of cancer. 
Overall, our results did not reveal differences in cancer cachexia progression with regards to 
hepatic oxidative phenotype or lipid content, but did show slight differences in glycogen content.  
Though our results did not reveal what was originally hypothesized, it is important to continue 
researching the mechanisms behind cancer cachexia. The more we know about the contributing 
metabolic processes, the more we can do to manage cachexia, and as a result try to prevent the 
physical effects and diminished quality of life resulting from cachexia. 
 Our data suggest that there were no differences in each of the variables we investigated. 
When trying to understand liver phenotype and cancer cachexia, our results suggest that these 
variables may not be attributable to progression of cancer cachexia. Though there were some 
differences found between 3 wk and 1 and 2 wk animals in percent area stained for glycogen, it is 
difficult to say there is a relationship without more data for support. In order to  understand liver 
phenotype, it may be beneficial to look further into glycogen content and into other processes in 
the liver that may contribute to liver hypertrophy and cancer cachexia. 
 Though our results do not suggest a relationship between progression of cancer cachexia 
and hepatic oxidative phenotype, lipid and glycogen content, there were some limitations that may 
have affected our results. The sample size was based off of a previous study done by Brown et al,  
but it is feasible that our study was underpowered, therefore affecting our anticipated outcome. 
Additionally, our analyses focused purely on histochemical analyses of lipid and glycogen contents 
and did not measure specific concentrations nor turnover of these metabolites, therefore it is 
possible that we were unable to measure such alterations using these techniques. 
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In summary, differences in liver sizes do not appear to be attributable to alterations in 
glycogen storage, oxidative phenotype or lipid content. Though there were no differences found, 
the increase in liver size suggests disruption of other processes in the liver. To our knowledge, 
this is the first investigation to attempt to demonstrate correlation between liver metabolic 
processes and cancer cachexia. Therefore, our study adds to current knowledge about and to 
underlying mechanisms related to cancer cachexia. For future projects, we will further 
investigate mechanisms of hepatic hypertrophy in order to determine the relationship between 
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